Fig. 2: RBMS1 ablation stimulates anti-tumor T cell immunity.

A Nude mice were subcutaneously injected with 4T1 cells with stable depletion of RBMS1. Pictures of the tumors removed after sixteen days were shown. B Tumors were weighed and plotted. C The average sizes of tumors were measured every day and plotted (n = 6, error bars indicate mean ± SD). D BALB/c mice were subcutaneously injected with 4T1 cells with stable depletion of RBMS1. Pictures of the tumors removed after twenty days were shown. E Tumors were weighed and plotted. Data represent mean ± SD (n = 6). P values were calculated by unpaired t test. F The average sizes of tumors were measured every day and plotted (n = 6, error bars indicate mean ± SD, P values were determined by two-way repeated measures ANOVA). G–H Quantification of intracellular cytokine staining of IFN-γ (G) and Granzyme B (H) in CD8⁺ T cell populations in the lymph nodes, spleen, and tumor of BALB/c mice. P values were calculated by unpaired Student’s t test. Error bars denote mean ± SD (n = 5). I Immunohistochemistry determination of RBMS1, PD-L1, Ki67 expression and CD8⁺ T cell infiltration into tumor tissues. Scale bars, 20 μm. Statistical results indicate means ± SD in each group (n = 5). J T cell-mediated tumor cell killing assay in MDA-MB-231, BT-549, and HCC1937 cells with stable depletion of RBMS1. Activated Jurkat cells were co-cultured with control or RBMS1-depleted TNBC cells at the T cell to tumor cell ratio of 10:1 (MDA-MB-231) or 20:1 (BT-549 and HCC1937). After 3 days, tumor cells were enumerated by flow cytometry. The quantitative ratio of dead cells is showed by the bar graph. Data represent mean ± SD, n = 3 independent repeats. P values were determined by One-way ANOVA with Dunnett multiple comparisons. For all panels, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.